PTGX

Protagonist Therapeutics Stock Analysis

AI Rating

Low
  • Quality5/10
  • Growth↓ 0/10
  • Value↓ 0/10
Protagonist Therapeutics sales and earnings growth
PTGX Growth
Low
  • Revenue Y/Y↓ -89.41%
  • EPS Y/Y↓ -145.86%
  • FCF Y/Y↓ -69.32%
Protagonist Therapeutics gross and profit margin trends
PTGX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -282.80%
  • ROIC 5Y↓ -20.33%
Protagonist Therapeutics net debt vs free cash flow
PTGX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Protagonist Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗